tetano
Editor, Senior Moderator
Clin Immunol
. 2022 Apr 24;109022.
doi: 10.1016/j.clim.2022.109022. Online ahead of print.
Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update
Wen Zhang[SUP] 1 [/SUP], Chenman Qin[SUP] 2 [/SUP], Yunyun Fei[SUP] 1 [/SUP], Min Shen[SUP] 1 [/SUP], Yangzhong Zhou[SUP] 3 [/SUP], Yan Zhang[SUP] 4 [/SUP], Xiaofeng Zeng[SUP] 5 [/SUP], Shuyang Zhang[SUP] 6 [/SUP]
Affiliations
Abstract
Last year in March, when coronavirus disease 2019 (COVID-19) was just beginning to spread around the world, we presented the potential benefits and controversies of anti-inflammatory therapy in COVID-19 patients based on the limited experience and proposed some types of anti-inflammatory drugs with potential therapeutic value, while without evidence-based data. In the past one more year, many clinical trials or real-world studies have been performed, either confirm or deny the efficacy of certain anti-inflammatory drugs in the treatment of COVID-19. In this review we summarize the progress of anti-inflammatory and immune therapy in COVID-19, including glucocorticoids, IL-6 antagonist, IL-1 inhibitor, kinase inhibitors, non-steroidal anti-inflammatory drugs and choloroquine/hydrocholoroquine.
Keywords: Anti-inflammation treatment; Coronavirus disease 2019 (COVID-19); Cytokine storm; Immune therapy.
. 2022 Apr 24;109022.
doi: 10.1016/j.clim.2022.109022. Online ahead of print.
Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update
Wen Zhang[SUP] 1 [/SUP], Chenman Qin[SUP] 2 [/SUP], Yunyun Fei[SUP] 1 [/SUP], Min Shen[SUP] 1 [/SUP], Yangzhong Zhou[SUP] 3 [/SUP], Yan Zhang[SUP] 4 [/SUP], Xiaofeng Zeng[SUP] 5 [/SUP], Shuyang Zhang[SUP] 6 [/SUP]
Affiliations
- PMID: 35477027
- DOI: 10.1016/j.clim.2022.109022
Abstract
Last year in March, when coronavirus disease 2019 (COVID-19) was just beginning to spread around the world, we presented the potential benefits and controversies of anti-inflammatory therapy in COVID-19 patients based on the limited experience and proposed some types of anti-inflammatory drugs with potential therapeutic value, while without evidence-based data. In the past one more year, many clinical trials or real-world studies have been performed, either confirm or deny the efficacy of certain anti-inflammatory drugs in the treatment of COVID-19. In this review we summarize the progress of anti-inflammatory and immune therapy in COVID-19, including glucocorticoids, IL-6 antagonist, IL-1 inhibitor, kinase inhibitors, non-steroidal anti-inflammatory drugs and choloroquine/hydrocholoroquine.
Keywords: Anti-inflammation treatment; Coronavirus disease 2019 (COVID-19); Cytokine storm; Immune therapy.
